A profound, often ineffable experience during a psychedelic session featuring a sense of unity, transcendence of time and space, noetic insight, sacredness, and positive mood. Measured by the Mystical Experience Questionnaire (MEQ-30). In Johns Hopkins trials, having a "complete" mystical-type experience — not dose alone — is the strongest predictor of long-term reductions in depression, anxiety, and addiction. (Griffiths et al., 2006; MacLean et al., 2011; Roseman et al., 2018)
A mystical-type experience is a profound, often ineffable experience that can occur during a full-dose psychedelic session. It has six core features (MacLean et al., 2011): a sense of unity with all things, transcendence of time and space, noetic quality (the feeling of encountering reality more directly than ordinary consciousness), sacredness, deeply positive mood, and ineffability (difficulty putting it into words).
It is measured by the Mystical Experience Questionnaire (MEQ-30), adapted from Ralph Hood's Mysticism Scale. A "complete" mystical-type experience is defined as scoring 60% or more on each of the four MEQ subscales in a single session.
Landmark Johns Hopkins trials (Griffiths et al., 2006, 2008, 2016; Roseman et al., 2018) found that having a complete mystical-type experience during a psilocybin session is the strongest single predictor of long-term reductions in depression, anxiety, and addiction — even more predictive than dose. This finding is one of the pillars of psychedelic-assisted therapy and the main reason preparation and setting are considered as clinically important as pharmacology.
Not every session produces a mystical-type experience, and absence of one does not mean no benefit. But the consistency of the correlation across studies is the strongest argument for high-dose, well-supported sessions over microdosing for severe depression, addiction, and end-of-life distress.
See: Psilocybin Therapy (/guides/psilocybin-therapy), Ego Dissolution (/glossary/ego-dissolution).
Mystical-type experience is the strongest predictor of therapeutic outcome across psilocybin trials — more than dose. It explains why preparation and set/setting are treated as clinically essential, not optional.